Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Healthcare Resource Utilization in Patients with Myeloproliferative Neoplasms: A Danish Nationwide Matched Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early- and late-onset posttransplant lymphoproliferative disorders among adult kidney and liver transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Henrik Gregersen
  • Valdas Peceliunas
  • Kari Remes
  • Fredrik Schjesvold
  • Niels Abildgaard
  • Hareth Nahi
  • Niels Frost Andersen
  • Annette Juul Vangsted
  • Tobias Wirenfeldt Klausen
  • Carsten Helleberg
  • Kristina Carlson
  • Ulf Christian Frølund
  • Per Axelsson
  • Olga Stromberg
  • Cecilie Hveding Blimark
  • Jacob Crafoord
  • Galina Tsykunova
  • Henrik Rode Eshoj
  • Anders Waage
  • Markus Hansson
  • Nina Gulbrandsen
View graph of relations

OBJECTIVE: We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma.

METHODS: This randomised, open-label, phase 2 trial included patients with first relapse of multiple myeloma after upfront ASCT who were re-induced with four cycles of carfilzomib, cyclophosphamide and dexamethasone. Two months after salvage, ASCT patients were randomised to either observation or maintenance therapy with iv carfilzomib 27 → 56 mg/sqm and p.o. dexamethasone 20 mg every second week. The study enrolled 200 patients of which 168 were randomised to either maintenance with carfilzomib and dexamethasone (n = 82) or observation (n = 86).

RESULTS: Median time to progression (TTP) after randomisation was 25.1 months (22.5-NR) in the carfilzomib-dexamethasone maintenance group and 16.7 months (14.4-21.8) in the control group (HR 0.46, 95% CI 0.30-0.71; P = .0004). The most common adverse events during maintenance were thrombocytopenia, anaemia, hypertension, dyspnoea and bacterial infections.

CONCLUSION: In summary, maintenance therapy with carfilzomib and dexamethasone after salvage ASCT prolonged TTP with 8 months. The maintenance treatment was in general well-tolerated with manageable toxicity.

Original languageEnglish
JournalEuropean Journal of Haematology
Volume108
Issue number1
Pages (from-to)34-44
Number of pages11
ISSN0902-4441
DOIs
Publication statusPublished - Jan 2022

Bibliographical note

© 2021 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.

    Research areas

  • Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Biomarkers, Tumor, Clinical Decision-Making, Dexamethasone/administration & dosage, Disease Management, Disease Susceptibility, Female, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multiple Myeloma/diagnosis, Oligopeptides/administration & dosage, Prognosis, Transplantation, Autologous, Treatment Outcome

ID: 79442037